

# CURRICULUM VITAE

DALAL ABD EL RAHMAN

ABOU EL ELLA



## ***PERSONAL I.D***

---

Family Name : Abou El Ella  
Middle Name : Abd El Rahman  
First Name : Dalal  
Date of birth : 9/4/1955  
Marital Status : Married and has three sons  
Languishes : English and Germany

## ***UNDERGRADUATE EDUCATION***

---

Bachelor Degree : 1974 – 1978, B. Sc. 1978 (*very good*), Faculty of Pharmacy, Cairo University

## ***GRADUATE EDUCATION***

---

Master Degree : 1979 – 1983 (Faculty of Pharmacy, Cairo and Bonn University, Germany).

Title : Synthesis & Degradation Mechanism of C-3 Phenylethylamine Substituted Pyrazolone.

supervised by : Prof. Dr. Gerhard Rücker, Prof. Dr. Mohammed Y. Ebaid,  
Prof. Dr. Attiat Eid and Dr. Michael Neugebauer.

Ph. D. Degree : 1985 – 1988 Karl Franzens University, Graz Austria – ÖAD Fellowship.

Title : Über die Reaktionen von Arylhydrazinen, Amidinen und Thioharnstoff mit  $\alpha$ ,  $\beta$ -ungesättigten Ketonen. Die dissertation wurde in deutsch geschrieben.

supervised by : Prof. Dr. W. Wendelin.

## ***POSITIONES HOLDED***

---

- Demonstrator** -1979 – 1983: at Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University.
- Assistant Lecturer** - 1983 – 1988: at Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University.
- Lecturer** - 1988 – 2000: at Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University.
- Associate professor** - 2000-2002: at Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University.
- 2002-2008: acting head of Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University.
- Professor** - 2008: at Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University.
- 2009-2011: Head of Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University.
- 2011-2012: Vice Dean for Community and Environmental Affairs-Faculty of Pharmacy-Ain Shams University.
- 2012-2013: Professor of Medicinal Chemistry -Faculty of Pharmacy- King Abdulaziz University- Jaddah-Saudi Arabia.
- 2013-2014: Professor of Pharmaceutical Chemistry - Pharmaceutical Chemistry Department- Faculty of Pharmacy-Ain Shams University.
- 2014-2015: head of Pharmaceutical Chemistry Department- Faculty of Pharmacy-Ain Shams University.
- 2016-2018: Dean of Faculty of Pharmacy-Nahda University-Beni Sueif
- 2018-2019: Vice President for Educational and Students Affairs - Nahda University-Beni Sueif.
- 2019-Now: Professor of Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University.

## ***PROFESSIONAL AND SCIENTIFIC EXPERIENCE***

---

### **1) Teaching Experience:**

#### **Undergraduate**

- (1982 – 1985): Demonstration and (1988 – 2002) Supervision of Pharmaceutical Chemistry, Practical Courses for Third and Fourth Year Students, Faculty of Pharmacy, Cairo University.
- (1989-2002 ) Participation in Supervision of Pharmaceutical Chemistry, Practical Courses and teaching the Theoretical Courses of Pharmaceutical Chemistry for fourth year students Faculty of Pharmacy, Cairo University.
- (2002-2012, 2013-2016, 2019-Now) Participation in Supervision the Practical and teaching the Theoretical Courses of Pharmaceutical Chemistry for third and fourth year students, Faculty of Pharmacy, Ain Shams University.
- (2002) Teaching the Practical and Theoretical Course of Pharmaceutical Chemistry for third year students, Faculty of Pharmacy, ***MIU (Part time)***.
- (2005-2012) Teaching the Practical and the Theoretical Course of Pharmaceutical Chemistry for third and fourth year students, Faculty of Pharmacy, ***GUC (Part time)***.
- (2012/2013) Participation in Teaching the Medicinal Chemistry courses for 3<sup>rd</sup> and 4<sup>th</sup> Year students-Faculty of Pharmacy- King Abdulaziz University- Jaddah-Saudi Arabia.
- (2014) Teaching the Practical and Theoretical Course of Pharmaceutical Chemistry for third year students, Faculty of Pharmacy, ***FUE (Part time)***.

#### **Postgraduate**

- Participation in Teaching ( 1996-2002) the Theoretical Special Courses (Drug Design) of Pharmaceutical Chemistry Master's degree students Faculty of Pharmacy, Cairo University.
- Participation in Teaching (2002-2012) the Special Courses (theoretical & practical Medicinal Chemistry and Drug Design) of Pharmaceutical Chemistry for Master's degree and Doctor's degree students, Faculty of Pharmacy, Ain Shams University.

2) Scientific activities:

A) \*Attendance of Qualifying Courses For Staff Members 10 / 01 / 1985.

\*Sharing in Lectures and Practical Training for Students and Staff Members in

Computer-

Aided Drug Design work shops which held in Faculty of Pharmacy, Ain Shams University in April 2003 and 2004.

\* Construct lab for Computer-Aided Drug Design and sharing in Lectures and Practical Training for Students and Staff Members in Computer-Aided Drug Design work shop which held in Faculty of Pharmacy, King Abdulaziz University- Jeddah-Saudi Arabia in 21-23 April 2013 and organizer in Drug Design workshop which held on 17-18 May 2015.

\* Construct lab for Computer-Aided Drug Design Sharing in Lectures and Practical Training for Students and Staff Members in Computer-Aided Drug Design work shop which held in Faculty of Pharmacy, Nahda University (NUB), Beni suef in May 2018.

B) Participation in Preparing the Practical and Theoretical Notes in Pharmaceutical Chemistry for Third and Fourth Year Students Faculty pharmacy, Ain Shams University.

C) Participation in preparing the course specs and annual reports of the pharmaceutical chemistry subjects in the department.

D) Participation in the construction of infrared structure for the faculty of Pharmacy–Ainshams University.

E) Participation in Quality Assurance and accreditation processes in Faculty of Pharmacy- Ain Shams University.

F) Examiner and evaluator in master and in PhD thesis (more than 30 theses).

G) Theses Supervision (55 theses):

H) Leadership in processes of Quality Assurance and accreditation in Faculty of Pharmacy- Nahda University (NUB).

I) Conferences:           \* *see attached*

J) List of Publications   \* *see attached*

## PUBLISHED ABSTRACTS OF CONTRIBUTIONS AT CONGRESSES

- 1) "3-Cyclohexyl-2-(cyclohexylidenmethyl)-1,5-diaryl-1,5-pentanediones: Synthesis and Reactions with Methylamine and Amidines" by W. Wendelin, U. Radner, E. Gößnitzer and D. Abou El Ella, *Fourteenth International Congress of Heterocyclic Chemistry, Antwerp, Belgium, 1993, Abstracts Book, PO2-99, University of Antwerp 1993.*
- 2) "Synthese und pharmakologische Wirkung von Benzo[h]chinolinaminen" von W. Wendelin, H.Keimelmayr, D. Abou El Ella, E. Korosec und E. Gößnitzer. *Tagung: 11. Wissenschaftliche Tagung der Österreichischen Pharmazeutischen Gesellschaft in Graz, 7. - 9.4.1994.*
- 3) "Dihydropyrimido[1,2-a]benzimidazoles: Elucidation of Structure, Tautomerism and Stereochemistry by high resolution NMR " by D. Abou El Ella, E. Gößnitzer and W. Wendelin, *Fifteenth International Congress of Heterocyclic Chemistry Taipei, Taiwan, 1995.*
- 4) "Synthesis, Structure, Stereochemistry and Tautomerism of Dodecahydro-benzimidazo[2,1-b]quinazolines" by D. Abou El Ella, E. Gößnitzer and W. Wendelin, *Fifteenth International Congress of Heterocyclic Chemistry Taipei, Taiwan, 1995.*
- 5) "Synthesis, Structure, Stereochemistry and Tautomerism of Benzimidazolamine-Benzylidentetralone-Condensates" by D. Abou El Ella, E. Gößnitzer and W. Wendelin, Hongkong *International Symposium on Heterocyclic Chemistry Hongkong 1995.*
- 6) "Ueber Regio- und Diastereoselektivitaet der Reaktionen von Hexahydro-2-benzimidazolamin Mit  $\alpha,\beta$ -ungesaettigten Ketonen" by E. Gößnitzer, W. Wendelin und D. Abou El Ella, *Tagung: 14. Wissenschaftliche Tagung der Österreichischen Pharmazeutischen Gesellschaft in Graz, 11. - 13.6.1998.*
- 7) "Benzopyranon Derivatives (part I): Synthesis of some 2,4,5-Imidazolinetrione Derivatives, Pyranobenzoxazine-9-one, and Pyranobenzoxazine-2,3,9-trione of Potential CNS Depressant Activity" by H. A. Abu Shady, S. L. El-Ansary, D. A. Abou El-Ella and N. A. H. Farag, **28<sup>th</sup> International Pharmaceutical Sciences Conference, Cairo, Egypt, 17-19 December-2002.**
- 8) Dalal A. Abou El Ella has attended "Al-Azhar 3<sup>rd</sup> international

**Conference for Pharmaceutical and Biological Sciences", 16-18 December, 2003.**

**9) "Benzopyranon Derivatives (part II): Synthesis of 4-Phenylbenzo[*b*]pyran-2-ones Attached to various Heterocyclic Ring Systems Possessing Potential CNS Depressant Activity" by H. A. Abu Shady, S. L. El-Ansary, D. A. Abou El-Ella and N. A. H. Farag, **9<sup>th</sup> Ibn Sina International Conference on Pure and Applied Heterocyclic Chemistry, Sharm El-Sheikh, Egypt, 11-14 December-2004.****

**10) "Molecular Design and synthesis of certain Thienopyrimidines as Potential  $\alpha_1$ -Antagonists" by Mohammed A. Ismail, Dalal A. Abou El-Ella, Khaled M. Abouzid, , **9<sup>th</sup> Ibn Sina International Conference on Pure and Applied Heterocyclic Chemistry, Sharm El-Sheikh, Egypt, 11-14 December-2004.****

**11) "Molecular Modeling and synthesis of Arylpiperazines Attached via Different Linkers to Various Heterocyclic Ring systems with Expected Dopaminergic Receptor Binding Affinity" by Dalal A. Abou El-Ella, Assiut University **5<sup>th</sup> Pharmaceutical Sciences Conference, Faculty of Pharmacy, Assiut, March 7-8<sup>th</sup>, 2006.****

**12) Dalal A. Abou El Ella has presented a research article for poster presentation in "1<sup>st</sup> Scientific conference of Faculty of Pharmacy, Cairo University, 29<sup>th</sup> March, 2008.**

**13) Dalal Abou El-Ella: Attended and participated in **Egyptian Pharmaceutical Society Conference, 20-22 December 2011****

**14) Dalal Abd el rahman Abou El Ella: Attended and participated in **Symposium of faculty of pharmacy Beni-Suef University on "Recent Advances in Pharmaceutical Research" held on Jan 12<sup>th</sup> 2011.****

**15) Dalal Abou El Ella: organizer the 1<sup>st</sup> Scientific Conference "**Scientific Research in Pharmacy: Future Insight**" which held at faculty of Pharmacy Nahda University – Beni-Suef on 6,7 March 2018.**

**16) Dalal Abou El Ella: participation as Advisory Board Member " **Recent Trends in Pharmaceutical Sciences**" held at Faculty of Pharmacy – Egyptian Russian University on 28<sup>th</sup>,29<sup>th</sup> April 2018.**

**17) Dalal Abou El Ella: Attended and participated in **1<sup>st</sup> National Dental Conference held at Nahda University – Beni-Suef on April 12-14 2019.****

**18) "Multidisciplinary Approaches in Pharmaceutical Science"where Dalal A. Abou El-Ella contributes as keynote speaker in the **2<sup>nd</sup> PUA International Conference held on 11<sup>th</sup>, 12<sup>th</sup> March 2020 at Pharos****

University in Alexandria, Egypt.

19) **Dalal A. Abou El-Ella** : Attended in the 5<sup>th</sup> annual Arab International Pharmacy Conference (AIPC): held at Hilton Heliopolis-Cairo- Egypt on March 27<sup>th</sup>, 28<sup>th</sup> 2021.

20) **Dalal A. Abou El-Ella**: Attended the 2<sup>nd</sup> International Conference of the Faculty of Pharmacy Delta University for Science and Technology “Future Prospect on Pharmaceutical Research and Healthcare” held at Intercontinental Semiramis-Cairo- Egypt at 2, 21 November 2021.

21) **Dalal A. Abou El-Ella** : Attended in the sixth annual Arab International Pharmacy Conference (AIPC): “Technology – based Healthcare Transformation” held at Hilton Heliopolis-Cairo- Egypt on March 19<sup>th</sup> – 20<sup>th</sup> 2022.

22) **Dalal A. Abou El-Ella**: Attended the 2<sup>nd</sup> International Conference of the Faculty of Pharmacy Delta University for Science and Technology “Future Prospect on Pharmaceutical Research and Healthcare” held at Intercontinental Semiramis-Cairo- Egypt at 2, 3 December 2023.

23) **Dalal A. Abou El-Ella**: Attended in the seventh annual Arab International Pharmacy Conference (AIPC): “Pharmacists Crucial Role in Healthcare Ecosystem” held at Hilton Heliopolis-Cairo- Egypt on March 6<sup>th</sup>, 7<sup>th</sup> 2023.

24) **Dalal A. Abou El-Ella**: Attended and poster reviewer in the 3<sup>rd</sup> International Conference on Pharmaceutical Sciences entitled "Advancements in Pharmacy Research" organized by Faculty of Pharmacy, Egyptian Russian University, 4<sup>th</sup> November, 2023.

25) **Dalal A. Abou El-Ella**: as a chairperson in 3<sup>rd</sup> International Conference of Faculty of Pharmacy (ICPASU), Ain Shams University, 18,19 November, 2023.

## **Publication List in Scopus**

1. Ismail HS, Khalil A, Taha RA, Lasheen DS, **Abou El Ella DA**. Design, Molecular Modelling and Synthesis of Novel Benzothiazole Derivatives as BCL-2 inhibitors. *Scientific Reports* 2023.
2. Shaker AM, Shahin MI, AboulMagd AM, Aleem SAA, Abdel-Rahman HM, **Abou El Ella DA**. Novel 1, 3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2. *Bioorganic Chemistry*. 2022;129:106143.
3. Mahmoud M, Abdollah MR, Elsesy ME, **Abou El Ella DA**, Zada SK, Tolba MF. The natural isoflavone Biochanin-A synergizes 5-fluorouracil anticancer activity in vitro and in vivo in Ehrlich solid-phase carcinoma model. *Phytotherapy Research*. 2022;36(3):1310-1325.
4. Elrazaz EZ, Serya RA, Ismail NS, Albohy A, **Abou El Ella DA**, Abouzid KA. Discovery of potent thieno [2, 3-d] pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. *Bioorganic Chemistry*. 2021;113:105019.
5. Abdelaleem EA, **Abou El Ella DA**, Mahmoud AM, Abdelhamid NS. Green analysis of newly approved binary omeprazole/aspirin mixture in presence of aspirin impurity using ultra-high-performance liquid chromatography and thin-layer chromatography methods. *Biomedical Chromatography*. 2021;35(2):e4986.
6. Morcoss MM, El Shimaa M, Ibrahim RA, Abdel-Rahman HM, Abdel-Aziz M, **Abou El-Ella DA**. Design, synthesis, mechanistic studies and in silico ADME predictions of benzimidazole derivatives as novel antifungal agents. *Bioorganic chemistry*. 2020;101:103956.
7. Elsayed NM, Serya RA, Tolba MF, Ahmed M, Barakat K, **Abou El Ella D**, Abouzaied K. Design, synthesis, biological evaluation and dynamics



- simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. *Bioorganic Chemistry*. 2019;82:340-359.
8. El Newahie AM, Nissan YM, Ismail NS, **Abou El Ella DA**, Khojah SM, Abouzid KA. Design and synthesis of new quinoxaline derivatives as anticancer agents and apoptotic inducers. *Molecules*. 2019;24(6):1175.
  9. Ewida MA, **Abou El Ella DA**, Lasheen DS, Ewida HA, El-Gazzar YI, El-Subbagh HI. Imidazo [2', 1': 2, 3] thiazolo [4, 5-d] pyridazinone as a new scaffold of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study. *Bioorganic Chemistry*. 2018;80:11-23.
  10. Ismail, R. S., Abou-Seri, S. M., Eldehna, W. M., Ismail, N. S., Elgazwi, S. M., Ghabbour, H. A., . . . **Abou El Ella, D. A.** Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. *European Journal of Medicinal Chemistry*. 2018;155:782-796.
  11. Shahin M, Roy j, Hanafi M, Wang D, Luesakul U, Chai Y, Muangsin N, Lasheen D, **Abou El Ella D**, Abouzid K. Synthesis and biological evaluation of novel 2-oxo-1, 2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma. *European Journal of Medicinal Chemistry*. 2018;155:516-530.
  12. Nowar RM, A Osman EE, Abou-Seri SM, El Moghazy SM, **Abou El Ella DA**. Design, synthesis and biological evaluation of some novel quinazolinone derivatives as potent apoptotic inducers. *Future Medicinal Chemistry*. 2018;10(10):1191-1205.
  13. Aly, R.M., Serya, R.A.T., El-Motwally, A.M., Abbas, S., **Abou El Ella, D.A.** Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity *Bioorganic Chemistry*, 2017, 75, pp. 368-392.
  14. Ewida MA, **Abou El Ella DA**, Lasheen DS, Ewida HA, El-Gazzar YI, El-Subbagh HI. Thiazolo [4, 5-d] pyridazine analogues as a new class of

- dihydrofolate reductase (DHFR) inhibitors: Synthesis, biological evaluation and molecular modeling study. *Bioorganic Chemistry*. 2017;74:228-237.
15. Ghorab M, Alsaid M, Samir N, Abdel-Latif G, Soliman A, Ragab F, **Abou El Ella D**. Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules. *European journal of medicinal chemistry*. 2017;134:304-315.
16. Eldehna W, Abou-Seri S, El Kerdawy A, Ayyad R, Hamdy A, Ghabbour H, Ali M, Abou **Abou El Ella D**. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives. *European Journal of Medicinal Chemistry*. 2016;113:50-62.
17. El Newahie AM, Ismail NS, **Abou El Ella DA**, Abouzid KA. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity. *Archiv der Pharmazie*. 2016;349(5):309-326.
18. Ghorab MM, Alsaid MS, Al-Ansary GH, Abdel-Latif GA, **Abou El Ella DA**. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers. *European journal of medicinal chemistry*. 2016;124:946-958.
19. Eldehna W, Fares M, Ceruso M, Ghabbour H, Abou-Seri S, Abdel-Aziz H, **Abou El Ella D**, Supuran C. Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII. *European Journal of Medicinal Chemistry*. 2016;110:259-266.
20. Elsayed NM, **Abou El Ella DA**, Serya RA, Tolba MF, Shalaby R, Abouzid KA. Design, synthesis and biological evaluation of indazole-pyrimidine based

- derivatives as anticancer agents with anti-angiogenic and antiproliferative activities. *MedChemComm*. 2016;7(5):881-899.
21. Abou-Seri SM, Eldehna WM, Ali MM, **Abou El Ella DA**. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation. *European journal of medicinal chemistry*. 2016;107:165-179.
22. Ibrahim DA, **Abou El Ella DA**, El-Motwally AM, Aly RM. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. *European Journal of Medicinal Chemistry*. 2015;102:115-131.
23. Ibrahim D, Lasheen D, Zaky M, Ibrahim A, Vullo D, Ceruso M, Supuran C, **Abou El Ella D**. Design and synthesis of benzothiazole-6-sulfonamides acting as highly potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII. *Bioorganic medicinal chemistry*. 2015;23(15):4989-4999.
24. Fares M, Ibrahim H, Aly M, Zada S, Ali M, Abou-Seri S, Abdel-Aziz H, **Abou El Ella D**. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking. *European journal of medicinal chemistry*. 2015;100:89-97.
25. Ismail MA, **Abou El Ella DA**, Abouzid KA, Abdou NS, Lahham A. Molecular modeling design, synthesis, and anti-hyperglycemic evaluation of certain 5-(aryl-alkoxy-benzylidene)-imidazolidine-2, 4-dione derivatives as potential PPAR $\gamma$  agonists. *Medicinal Chemistry Research*. 2015;24:2115-2126.
26. Farag DB, Farag NA, Esmat A, Abuelezz SA, Ibrahim EA-S, **Abou El Ella DA**. Synthesis, 3D pharmacophore, QSAR and docking studies of novel quinazoline derivatives with nitric oxide release moiety as preferential COX-2 inhibitors. *MedChemComm*. 2015;6(2):283-299.
27. Shahin MI, **Abou El Ella DA**, Ismail NS, Abouzid KA. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold. *Bioorganic Chemistry*. 2014;56:16-26.

28. **Abou El-Ella DA**, Hussein MM, Serya RA, et al. Molecular design and synthesis of 1, 4-disubstituted piperazines as  $\alpha$ 1-adrenergic receptor blockers. *Bioorganic Chemistry*. 2014;54:21-30.
29. Fahmy HH, Khalifa NM, **Abou El Ella DA**, Ismail MA, Mostafa NM, Hamdy AA. Synthesis and antifungal activity of some new substituted 5, 7-Diiodo-8-Hydroxy Quinoline derivatives. *Life Science Journal*. 2013;10(4):362-368.
30. Khalifa NM, Fahmy HH, **Abou El Ella DA**, Ismail MA, Mostafa NM, Al-Omar MA. Synthesis and Reactions of Some Novel 5, 7-diiodo-8-Hydroxyquinoline Candidates as Antimicrobial Agentes. *Life Science Journal*. 2013;10(4):470-476.
31. Ismail MA, **Abou El Ella DA**, Abouzid KA, Mahmoud AH. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. *Bioorganic medicinal chemistry*. 2012;20(7):2455-2478.
32. Hamed MM, **Abou El Ella DA**, Keeton AB, et al. Quinazoline and tetrahydropyridothieno [2, 3-d] pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. *MedChemComm*. 2013;4(8):1202-1207.
33. Lasheen DS, Ismail MA, **Abou El Ella DA**, et al. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity. *Bioorganic medicinal chemistry*. 2013;21(10):2742-2755.
34. Al-Ansary GH, Ismail MA, **Abou El Ella DA**, Eid S, Abouzid KA. Molecular design and synthesis of HCV inhibitors based on thiazolone scaffold. *European Journal of Medicinal Chemistry*. 2013;68:19-32.
35. Hamed MM, **Abou El Ella DA**, Keeton AB, et al. 6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and-Resistant Tumor Cell Lines. *ChemMedChem*. 2013;8(9):1495-1504.

36. Hamed MM, **Abou El Ella DA**, Keeton AB, et al. 6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and-Resistant Tumor Cell Lines. *ChemMedChem*. 2013;8(9):1495-1504.
37. Mahmoud AH, **Abou El Ella DA**, Ismail MA, Abouzid KA. A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues. *European journal of medicinal chemistry*. 2012;57:468-482.
38. Abou El Ella DA, Ghorab MM, Heiba HI, Soliman AM. Synthesis of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety for evaluation as anticancer and radiosensitizing agents. *Medicinal Chemistry Research*. 2012;21:2395-2407.
39. **El Ella, D.A.A.E.**, Saleh, K.A., Hassan, M., ...El-Araby, M.E., Abouzid, K.A.M. Synthesis and anti-proliferative activity of substitutedanilinoquinazolines and its relation to EGFR inhibition *Arzneimittel-Forschung/Drug Research*, 2012, 62(8), pp. 360-366.
40. Ismail, M.A.H., **Abou El Ella, D.A.**, Abouzid, K.A.M., Mahmoud, A.H., Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives *Bioorganic and Medicinal Chemistry*, 2012, 20(7), pp. 2455–2478.
41. Abou-Seri SM, Abouzid K, **Abou El Ella DA**. Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as  $\alpha$ 1-adrenoreceptor antagonists. *European Journal of Medicinal Chemistry*. 2011;46(2):647-658.
42. Ismail MAH, **Abou El Ella D**, Abouzid K, Al-Ansary G. Computer-based drug design, synthesis and biological evaluation of new pyrimidinone derivatives linked to arylpiperazine and 2'-carbethoxy-biphenylmethyl moieties as  $\alpha$ 1-adrenoceptor antagonists and angiotensin II AT1 receptor antagonists.

- Die Pharmazie-An International Journal of Pharmaceutical Sciences.* 2010;65(11):794-800.
43. Ismail MA, Lehmann J, **Abou El Ella DA**, Albohy A, Abouzid KA. Lonazolac analogues: molecular modeling, synthesis, and in vivo anti-inflammatory activity. *Medicinal chemistry research.* 2009;18:725-744.
44. Ismail MA, Aboul-Enein MN, Abouzid KA, **Abou El Ella DA**, Ismail NS. ACE inhibitors hypothesis generation for selective design, synthesis and biological evaluation of 3-mercapto-2-methyl-propanoyl-pyrrolidine-3-imine derivatives as antihypertensive agents. *Bioorganic medicinal chemistry.* 2009;17(10):3739-3746.
45. Abd El-Salam O, **Ella D**, Ismail N, Abdullah M. Synthesis, docking studies and anti-inflammatory activity of some 2-amino-5, 6, 7, 8-tetrahydroquinoline-3-carbonitriles and related compounds. *Die Pharmazie-An International Journal of Pharmaceutical Sciences.* 2009;64(3):147-155.
46. **Abou El Ella DA**, Ghorab MM, Noaman E, Heiba HI, Khalil AI. Molecular modeling study and synthesis of novel pyrrolo [2, 3-d] pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities. *Bioorganic Medicinal Chemistry Research.* 2008;16(5):2391-2402.
47. Ghorab MM, Heiba HI, Khalil AI, **Abou El Ella DA**, Noaman E. Computer-based ligand design and synthesis of some new sulfonamides bearing pyrrole or pyrrolopyrimidine moieties having potential antitumor and radioprotective activities. *Phosphorus, Sulfur, Silicon the Related Elements.* 2007;183(1):90-104.
48. Ismail MA, Barker S, **Abou El Ella DA**, Abouzid KA, Toubar RA, Todd MH. Design and synthesis of new tetrazolyl-and carboxy-biphenylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists. *Journal of medicinal chemistry.* 2006;49(5):1526-1535.

49. Wendelin W, Goessnitzer E, **EI Ella DA**. Synthesis and Structure Elucidation of Pyrimidobenzimidazoles and Fused Derivatives II [1].  
Dodecahydrobenzimidazo-[2, 1-b] quinazolines and  
Decahydrobenzimidazo-[2, 1-b] benzo [h] quinazolines [2]. *Monatshefte für Chemie/Chemical Monthly*. 2000;131:353-374.
50. Wendelin W, Keimelmayr H, Gössnitzer E, **Abou EI Ella D**. Synthesis, structural analysis and pharmacological effects of N<sup>2</sup>-substituted 3, 4-dihydrobenzo [h] quinolin-2-amines. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*. 1996;51(11):816-822.
51. Wendelin W, Zarfl J, Goessnitzer E, **Abou EI Ella D**. Synthesis, Structure and Pharmacological Effects of N<sup>3</sup>-Substituted 1, 2-Dihydrobenzo [f] quinolin-3-amines. *SCIENTIA PHARMACEUTICA*. 1996;64:719-728.
52. **Ella D**, Gonitzer E, Wendelin W. Synthesis and structural elucidation of pyrimido-[1, 2-a] benzimidazoles and fused derivatives of dihydropyrimido [1, 2-a] benzimidazoles [1, 2]. *Heterocycl Chem*. 1996;33:373.
53. **EI-Ella DA**, Neugebauer M, Eid A, Ebied MY, Rücker G. Investigations on the Stability of Famprofazon N-Oxide. *Archiv der Pharmazie*. 1984;317(1):89-91.
54. Serya RAT, Abbas AH, Ismail NSM, Esmat A, **Abou EI Ella DA**. Design, synthesis and biological evaluation of novel quinazoline-based anti-inflammatory agents acting as PDE4B inhibitors. *Chemical Pharmaceutical Bulletin*. 2015;63(2):102-116.

#### **Publications in international journals not cited in Scopus**

1. Goessnitzer E, Wendelin W, **Abou EI Ella DA**. Ueber Regio-und Diastereoselektivitaet der Reaktionen von Hexahydro-2-benzimidazolamin mit , -ungesaettigten Ketonen. *Scientia pharmaceutica*. 1998;66:S47-S47.
2. Wendelin W, Zarfl J, Goessnitzer E, **Abou EI Ella DA**. Bridged Derivatives of Phenyl-and Naphthylethylamine and Nitrogen Analogous Compounds. Part 5. Synthesis, Structure and Pharmacological Effects of N<sup>3</sup>-Substituted 1, 2-Dihydrobenzo (f) quinolin-3-amines. *ChemInform*. 2010;28(18).

3. Wendelin W, Zarfl J, Goessnitzer E, **Abou El Ella DA**. Uber Synthese, Struktur Und Pharmakologische Wirkungen Von N3-sustituierten 1,2-dihydrobenzofchinolin-3-aminen. *Scientia pharmaceutica*. 1996; 64(3-4):719-728.
4. Aly RM, Serya R, Amira M, Al-Ansary GH, **Abou El Ella DA**. Quinoline-based small molecules as effective protein kinases inhibitors. *Journal of American Science*. 2016;12(5):10-32.
5. Mahmoud M, El-Sesy M, Tolba MF, **Abou El Ella D**. Abstract B47: A novel combination of Biochanin-A/5-Fluorouracil against colon cancer: Impact on Wnt/beta-catenin signaling. *Cancer Research*. 2017;77(6\_Supplement):B47-B47.
6. Ismaila MA, **Abou El Ella DA**, Abouzid KA, Jaballah M. Design, Synthesis and Virtual Screening of Certain 2-Pyrazolin-5-one and Pyrazolidine-3,5-Dione Derivatives as Potential PPAR (gamma) Agonists. *International Journal of Pharmaceutical Sciences Research*. 2012;3(10):3746.
7. Ghorab MM, **El Ella D**, Heiba HI, Soliman AM. Synthesis of certain new thiazole derivatives bearing a sulfonamide moiety with expected anticancer and radiosensitizing activities. *Journal of Materials Science Engineering A: Structural Materials: Properties, Microstructure Processing*. 2011;1(5):684-691.
8. Mohamed IA, **Abou El Ella DA**, Abouzid KA, Lasheen DS. Molecular Modeling Design, Synthesis and Biological Evaluation of New Imidazoline Derivatives Linked as  $\alpha$ 1-AR Antagonists and Ang II Receptor Antagonists. *Jordan Journal of Chemistry*. 2009.

#### **National Publication (EKB)**

1. Morcoss MM, Abdelhafez ES, Abdel-Rahman HM, Abdel-Aziz M, El-Ella A, **Dalal A**. Novel Benzimidazole/Hydrazone Derivatives as Promising Anticancer Lead Compounds: Design, Synthesis, and Molecular Docking Study. *Journal of advanced Biomedical Pharmaceutical Sciences*. 2020;3(2):45-52.



2. Abbas S, Abdou NS, Lasheen DS, **Abou El Ella DA**. Apoptosis in cancer: from pathogenesis to discovery of advanced selective Bcl-2 family inhibitors. *Archives of Pharmaceutical Sciences Ain Shams University*. 2019;3(1):37-54.
3. Ismail RS, Ismail NS, Abuserii S, **Abou El Ella DA**. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. *Future Journal of Pharmaceutical Sciences*. 2016;2(1):9-19.
4. Ismail NS, Ali EM, Ibrahim DA, Serya RA, **Abou El Ella DA**. Pyrazolo [3, 4-d] pyrimidine based scaffold derivatives targeting kinases as anticancer agents. *Future Journal of Pharmaceutical Sciences*. 2016;2(1):20-30.
5. Elsayed NM, **Abou El Ella DA**, Serya RA, Abouzid KA. Targeting apoptotic machinery as approach for anticancer therapy: Smac mimetics as anticancer agents. *Future Journal of Pharmaceutical Sciences*. 2015;1(1):16-21.
6. Elrazaz EZ, Serya RA, Ismail NS, **Abou El Ella DA**, Abouzid KA. Thieno [2, 3-d] pyrimidine based derivatives as kinase inhibitors and anticancer agents. *Future Journal of Pharmaceutical Sciences*. 2015;1(2):33-41.
7. **Abou El Ella DA**, U Müller FK. A new scaffold for D3 dopaminergic affinity containing arylpiperazine fragment: molecular modeling, synthesis, in vitro and in vivo pharmacological evaluation. *Bulletin of Pharmaceutical Sciences Assiut*. 2007;30(2):259-273.
8. S.M El Moghazy A, **Dalal Abou El Ella**, SM AS, MY E. Synthesis, molecular modeling and anticancer activity of certain acridine derivatives. *Egyptian Journal of Pharmaceutical Sciences*. 2002.
9. Aly, S.M., **Abou El Ella, Dalal**, Seri, S. M. A., & Ebeid, M. Y. Synthesis, Molecular Modeling and Anticancer Activity of Certain Acridine Derivatives. *Egyptian Journal of Pharmaceutical Sciences*, 2003, 43(1/2), 73–104.
10. **Dalal A. Abou El Ella**, Synthesis and Anti-HIV-1 Activity of Some Naphtho[2',3':4,5]imidazo[1,2- a]pyrimidine, Naphtho[2',3':4,5]imidazo[2,1-b]quinazoline and Octahydrobenzo [4,5]imidazo[1,2-a]pyrimidine Derivatives", *Bull. Fac. Pharm. Cairo Univ.*, 35 (1), 1-7 (1997).

11. **Dalal Abou El Ella**, Synthesis and Stereochemical Structural Elucidation of some Partially Reduced Benzimidazo[2,1-b]quinazoline Derivatives, *Bull. Fac. Pharm. Cairo Univ.*, 37 (3), 73-81, 1999.
12. N.M.El Sayed, **Dalal Abou El Ella**, A. E. Farag, M. Ebeid and N. A. Moneib, New Pyrimidopyrimidoazepine Derivatives of expected Antibacterial Effect, *Bull. Fac. Pharm. Cairo Univ.*, 38 (2), 19-29, 2000.
13. H. A. Abu Shady, S. L. El-Ansary, **Dalal A. Abou El-Ella**, N. A. H. Farag Benzopyranon Derivatives (part I): Synthesis of Various Benzopyranoyl-imidazolidine-triones, Arylpyranobenzoxazinone, pyranobenzoxazinetrione and Benzopyranoyl-triazinetrione derivatives of Potential CNS Depressant Activity, *Bull. Fac. Pharm. Cairo Univ.*, 42(3), 31-42, 2004.

## ملخص الأنشطة العلمية والتدرج الوظيفي

- 1 - ماجستير في الكيمياء الصيدلانية اشراف مشترك (كلية الصيدلة جامعة القاهرة و كلية الصيدلة جامعة بون-المانيا) – 1979  
1983
- 2 - دكتوراه في الكيمياء الصيدلانية من جامعة كارل فرانس –جراتس-النمسا 1985 – 1988
- 3 - مهمة علمية من جامعة عين شمس لمدة 3 شهور بجامعة فيينا-النمسا
- 4 - رئيس قسم الكيمياء الصيدليه –كلية الصيدلة- جامعة عين شمس 2002-2008, 2009-2011, 2014-2015
- 5 - عضو في جميع لجان-كلية الصيدلة- جامعة عين شمس منذ 2002-الآن: لجنة شئون التعليم و الطلاب ، لجنة الدراسات العليا والبحوث، لجنة شئون المجتمع والبيئة
- 6 - عضو في مجلس-كلية الصيدلة- جامعة عين شمس منذ 2002-الآن
- 7 - مشارك في تطوير مقرارات الكيمياء الصيدليه و تصميم الادويه العمليه والنظريه بقسم الكيمياء الصيدليه -كلية الصيدلة- جامعة عين شمس.
- 8 - مشارك في تصميم معمل تصميم أدويه يقسم الكيمياء الصيدليه –كلية الصيدلة- جامعة عين شمس وقد تم انشاءه سنة 2003 وتم تطويره سنة 2009 و عقد ورش عمل في برنامج تصميم الادوية باستخدام الحاسوب. انشاء معمل تصميم ادوية في كلية الصيدلة بجامعة الملك عبد العزيز بمدينة جدة بالمملكة العربية السعودية (2013) وايضا انشاء معمل تصميم ادوية بكلية الصيدلة جامعة النهضة ببني سويف (NUB، 2017)
- 9 - مشارك في برامج الجوده بكلية الصيدلة- جامعة عين شمس. و تكوين فريق وقيادته للحصول على الاعتماد والجودة في كلية الصيدلة جامعة النهضة
- 10 - محكم في مجلات عالميه
- 11 - محكم في اللجنة العلمية لترقية الاساتذة المساعدين و الاساتذة تخصص الكيمياء الصيدلية و الحيوية
- 12 - محكم في لجنة جائزة اكديما 2020
- 13 - محكم في لجنة الجائزة التقديرية بجامعة عين شمس 2022
- 14 - وكيل الكلية لشئون خدمة المجتمع و تنمية البيئة 2011-2012- كلية الصيدلة- جامعة عين شمس
- 15 - استاذ الكيمياء الطبيه-كلية الصيدلة-جامعة الملك عبد العزيز-جدة-المملكة العربية السعودية (2012-2013)
- 16 - استاذ الكيمياء الصيدليه-كلية الصيدليه-كلية الصيدله-جامعة عين شمس في 2013-2014
- 17 - مشرف ومحكم اكثر من 60 رسالة ماجستير و دكتوراه
- 18 - عضو في لجنة التظلمات لترقية الاساتذة المساعدين والاساتذة بجامعة عين شمس 2021 الي الآن
- 19 - عضو في اللجنة العلمية لترقية الاساتذة المساعدين و الاساتذة تخصص الكيمياء الصيدلية الحبوية بالمجلس الاعلى للجامعات (الدورة الرابعة 2022-2025)
- 20 - عضو في اللجنة الدائمة لترقية الاساتذة المساعدين و الاساتذة تخصص الكيمياء الصيدلية والكيمياء العضوية والكيمياء التحليلية بكلية الصيدلة جامعة الأزهر دورة 2021.

٢١- عميد كلية الصيدلة – جامعة النهضة ببني سويف من أغسطس ٢٠١٦ الي أغسطس ٢٠١٨

٢٢- نائب رئيس جامعة النهضة لشئون التعليم و الطلاب في ٢٠١٩-٢٠١٨

٢٣- H-index = 23 by Scopus and 26 by google scholar 2023

٢٤- نشر ٦٤ بحثا دوليا و ١٣ بحثا محليا

٢٥- استاذ الكيمياء الصيدلية المتفرغ – كلية الصيدلة – جامعة عين شمس أغسطس ٢٠١٩ الي الآن